Penumbra Receivables 2014-2025 | PEN

Penumbra receivables for the quarter ending March 31, 2025 were $0.168B, a 12.5% decline year-over-year.

  • Penumbra receivables for 2024 were $0.168B, a 16.9% decline from 2023.
  • Penumbra receivables for 2023 were $0.202B, a 0.79% decline from 2022.
  • Penumbra receivables for 2022 were $0.203B, a 51.85% increase from 2021.

Penumbra Receivables 2014-2025 | PEN

  • Penumbra receivables for 2024 were $0.168B, a 16.9% decline from 2023.
  • Penumbra receivables for 2023 were $0.202B, a 0.79% decline from 2022.
  • Penumbra receivables for 2022 were $0.203B, a 51.85% increase from 2021.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$171.9B
Thermo Fisher Scientific (TMO)$161.4B
Alcon (ALC)$45.6B
Edwards Lifesciences (EW)$42B
IDEXX Laboratories (IDXX)$33.3B
DexCom (DXCM)$26.9B
IQVIA Holdings (IQV)$25.4B
STERIS (STE)$21.8B
Mettler-Toledo (MTD)$20.9B
Waters (WAT)$19.1B
SONOVA HOLDING (SONVY)$17.3B
Fresenius Medical Care AG KGaA (FMS)$13.9B
Hologic (HOLX)$12.9B
Sysmex ADR (SSMXY)$11.8B
Globus Medical (GMED)$9.8B
Masimo (MASI)$8.2B
Teleflex (TFX)$6B
Glaukos (GKOS)$5.2B
Integer Holdings (ITGR)$4.1B
TransMedics (TMDX)$3B
PROCEPT BioRobotics (PRCT)$2.9B
Veracyte (VCYT)$2.4B
Nihon Kohden (NHNKY)$2.1B
LivaNova (LIVN)$1.9B
Elekta AB (EKTAY)$1.9B
Alphatec Holdings (ATEC)$1.5B
Integra LifeSciences Holdings (IART)$1.2B
Pulse Biosciences (PLSE)$1.2B
Tandem Diabetes Care (TNDM)$1.1B
Paragon 28 (FNA)$1.1B